Short answer
Progyny, Inc. (PGNY) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $341M (up 8.9% year over year) with net income of $26M.
Q3 2026 key financials · XBRL
- Revenue
- $341M
- +8.9% YoY · −2.6% QoQ
- Net income
- $26M
- +89.4% YoY · −6.4% QoQ
- Operating margin
- 10.3%
- Gross margin
- 24.5%
- EPS (diluted)
- $0.32
- +113.3% YoY · −5.9% QoQ
Source: XBRL data from the Progyny, Inc. (PGNY) Q3 2026 10-Q on SEC EDGAR. USD.
Progyny, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $341.254M, up 9% YoY, fertility benefits $21.4M increase, Progyny Rx $6.5M increase
- Gross margin 24.5% vs 23.2%, operating margin 10.3% vs 6.9% YoY
- Net income $26.252M vs $13.864M, adjusted EBITDA margin 17.1% vs 17.5%
- Cash $116.8M and marketable securities $78.8M at September 30, 2026
- Nine-month operating cash flow $152.979M, share repurchases $230.9M at $23.83 average price
Risk Factors
- Newly added guidance risk: November 4, 2026 fourth-quarter and full-year guidance exposed to revisions and consensus shortfalls
- Most material regulatory update: February 3, 2026 PBM reforms require rebate disclosure, 100% consumer pass-through, reporting and audits
- Competitive risk: Healthcare consolidation may shift clients toward integrated solutions and increase provider negotiating power
- Operational risk: Specialty-pharmacy disruptions could delay fertility treatments and reduce Progyny Rx revenue
- Concentration risk: Technology-industry clients represent a significant revenue share, despite no client exceeding 10% of revenue
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Progyny, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.